- Home
- ACTG vs CKPT Comparison
ACTG vs CKPT Comparison
Compare ACTG & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTG
- CKPT
- Stock Information
- Founded
- ACTG 1993
- CKPT 2014
- Country
- ACTG United States
- CKPT United States
- Employees
- ACTG N/A
- CKPT N/A
- Industry
- ACTG Multi-Sector Companies
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- ACTG Miscellaneous
- CKPT Health Care
- Exchange
- ACTG Nasdaq
- CKPT Nasdaq
- Market Cap
- ACTG 363.5M
- CKPT 361.1M
- IPO Year
- ACTG 1996
- CKPT 2017
- Fundamental
- Price
- ACTG $3.73
- CKPT $4.26
- Analyst Decision
- ACTG
- CKPT Buy
- Analyst Count
- ACTG 0
- CKPT 3
- Target Price
- ACTG N/A
- CKPT $4.33
- AVG Volume (30 Days)
- ACTG 263.8K
- CKPT 2.1M
- Earning Date
- ACTG 05-08-2025
- CKPT 05-13-2025
- Dividend Yield
- ACTG N/A
- CKPT N/A
- EPS Growth
- ACTG N/A
- CKPT N/A
- EPS
- ACTG N/A
- CKPT N/A
- Revenue
- ACTG $222,414,000.00
- CKPT $41,000.00
- Revenue This Year
- ACTG $141.36
- CKPT $102,182.93
- Revenue Next Year
- ACTG N/A
- CKPT $351.71
- P/E Ratio
- ACTG N/A
- CKPT N/A
- Revenue Growth
- ACTG 65.22
- CKPT N/A
- 52 Week Low
- ACTG $2.70
- CKPT $1.80
- 52 Week High
- ACTG $5.74
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- ACTG 57.69
- CKPT 80.26
- Support Level
- ACTG $3.58
- CKPT $4.14
- Resistance Level
- ACTG $3.87
- CKPT $4.20
- Average True Range (ATR)
- ACTG 0.13
- CKPT 0.03
- MACD
- ACTG 0.00
- CKPT -0.00
- Stochastic Oscillator
- ACTG 36.59
- CKPT 85.71
About ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.